Vivos Therapeutics Announces Pricing of $21M Initial Public Offering

Vivos Therapeutics, Inc. (“Vivos”), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced the pricing of its initial public offering of 3,500,000 shares of its common stock at a public offering price of $6.00 per share. The shares of common stock are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “VVOS” on Friday, December 11, 2020. About Vivos Therapeutics, Inc.Vivos Therapeutics Inc. is a medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). We believe our products and technology represent a significant improvement in the treatment of mild-to-moderate OSA versus other treatments such as continuous positive airway pressure (or CPAP). For more information visit www.vivoslife.com.
（以上内容由医药魔方AI生成）